Cyclacel Pharmaceuticals Profit Margin

The latest profit margin for CYCC is -213.82% as of June 2026. That compares with 8726.37% in the prior-year period — down 102.5% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Cyclacel Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYCC's profit margin moved from 8726.37% to -213.82% — a 102.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cyclacel Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, CYCC currently prints -213.82% for profit margin, while the sector average sits near 21.34%. That is roughly 1102.2% below the sector mean. Large gaps often invite a closer look at Cyclacel Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Cyclacel Pharmaceuticals converts resources into returns. At -213.82%, CYCC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 8726.37% in the prior-year period — down 102.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CYCC's profit margin (-213.82%), review year-over-year change from 8726.37%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.